| scholarly article | Q13442814 |
| P2093 | author name string | K G Seshadri | |
| M H B Kirubha | |||
| P2860 | cites work | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 |
| The biology of incretin hormones | Q34499706 | ||
| Gut hormones as potential new targets for appetite regulation and the treatment of obesity | Q37057996 | ||
| What role will 'gliptins' play in glycemic control? | Q37168388 | ||
| Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. | Q37313418 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin | Q51468797 | ||
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes | Q51471806 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial | Q51478110 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study | Q51483804 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone | Q51484788 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes | Q51484798 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus | Q51489068 | ||
| Sitagliptin | Q79890760 | ||
| Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes | Q94681234 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 608-614 | |
| P577 | publication date | 2009-11-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Indian Journal of Pharmaceutical Sciences | Q6020807 |
| P1476 | title | Gliptins: a new class of oral antidiabetic agents | |
| P478 | volume | 71 |
| Q37720797 | Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties | cites work | P2860 |
Search more.